
    
      This is a phase 2, randomized, two-arm, open-label study designed to evaluate the efficacy
      and safety of Duvelisib Administered in Combination with Rituximab vs R-CHOP in Subjects with
      Relapsed/Refractory Follicular Lymphoma.
    
  